Market Research Logo

Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over 90% of the patients suffering from reduced kidney function are unaware of their medical condition. In the US, 15% of adults are reported to be suffering from mild or severe forms of CKD. In fact, the mean global prevalence of CKD, across all five stages of the disease, is estimated to be 13.4%. Limited availability of epidemiological data, lack of awareness, late diagnosis and inappropriate / incorrect treatment are some of the factors responsible for elevating disease incidence. It is also worth noting that developed nations spend over 2-3% of their annual healthcare budget on the treatment of end-stage renal disease (ESRD); however, the economic burden associated with milder forms of CKD is almost double the total costs incurred in the treatment of ESRD. Further, in the US, the disease has been estimated to incur combined direct and indirect costs ranging between USD 1,183 - USD 35,292 per patient, per month.

Existing therapeutic options have already been proven to be inadequate in containing the progression of the disease and its symptoms in the long term. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions and therapies that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital funding in order to expedite the development of potential therapeutic options for better disease management.

SCOPE OF THE REPORT
The “Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights” report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of chronic kidney disease. Figure 1.1 summarizes the scope of the report and the specific modules that have been covered in detail in the document.

Figure 1.1 Chronic Kidney Disease: Scope and Competitive Insights

Source: Roots Analysis

Amongst other elements, the report includes:
A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease modifying agent or drugs offering symptomatic relief), mechanism of action, and route of administration of the drugs being developed for the treatment of chronic kidney disease.

An in-depth analysis of the product pipeline and developer companies, featuring three schematic representations; these include [A] a heptagon representation, highlighting the distribution of the marketed and development stage molecules based on the target clinical condition, [B] a 2X2 grid analysis, representing the distribution of drug candidates across various disease indications, dosing frequencies and stages of development, and [C] a diagrammatic representation of the regional landscape of industry players involved in the development of drugs in this domain, distributed based on the location of their headquarters.

An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population (for the trial in the highest phase of development), route of administration, treatment type (disease modifying agent and drugs offering symptomatic relief) and dosing frequency (for quantifying clinical attractiveness), and target patient population, expected launch date and size of developer company (for quantifying commercial attractiveness).

An analysis highlighting the key unmet needs across chronic kidney disease, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, patient blogs and the views of key opinion leaders expressed on online platforms.

An insightful competitive analysis, highlighting the key players in the domain on the basis of the strength of their respective development portfolios, taking into account company size and the stage of development of lead molecules in their respective pipelines.

A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.

An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and commercialization agreements, manufacturing agreements and others

An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from secondary sources. The opinions and insights presented in this study were influenced by inputs of several key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. The analysis of content presented on informal (100 patient blogs and over 3,000 social media posts) and formal (180 scientific articles) literary sources, and the opinions expressed by industry experts confirm the existence of a significant unmet need within the chronic kidney disease market. Some of the unaddressed concerns suggested across multiple portals include improved therapeutic strategies, better management of comorbidities, lack of awareness related to the conditions leading to chronic kidney disease, high economic burden, unavailability of dialysis centers and poor quality of life.

2. Presently, over 160 product candidates are being evaluated across various stages of development for the management / treatment of chronic kidney disease. Of these, 24% are in the preclinical or discovery phase. Amongst the drugs that are under clinical development, 33 are in phase III / pre-registration, 47 in phase II, and 22 in phase I and phase I/II trials. Interestingly, since 2012, 22 product candidates have been commercialized; examples include JYNARQUE® (2018), Parsabiv™ (2017), RAYALDEE® (2016) and VELTASSA® (2015).

3. Majority of novel drug candidates (close to 70%) are disease modifying agents, while nearly 30% designed to provide symptomatic relief only. It is worth highlighting that 75% of pipeline candidates are small molecules, and the rest are biologics. Further, most are being developed as monotherapies (close to 75%), whereas nearly 25% are currently being investigated as combination therapies.

4. The market landscape is characterized by the presence of large (31), mid-sized (33) and small-sized companies (47). Examples of prominent large companies engaged in this domain include (in alphabetical order, no selection criteria) Amgen, Asahi Kasei Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer and Sanofi. The growing unmet need within this domain has spurred the establishment of many start-ups / small-sized companies in the recent years; examples include (in alphabetical order, no selection criteria) Algomedix, Angion Biomedica, Anthera Pharmaceuticals, Apellis Pharmaceuticals, Complexa, Ember Therapeutics, Genkyotex, Goldfinch Bio, inRegen, Kezar Life Sciences, Lanthio Pharma, Orbis Biosciences, Redx pharma, Sanifit and Serodus.

5. Stakeholders in the industry have forged several strategic partnerships in the recent past; we observed that 28% of the agreements that were signed between 2015 and 2018 were related to research and development. These were followed by development and commercialization agreements (23%), licensing agreements (22%), commercialization agreements (15%), acquisitions (5%), mergers (5%), and manufacturing agreements (2%). Examples of recently inked deals include collaborations between Novo Nordisk and Evotec (August 2018), Resverlogix and Medison Pharma (January 2018), and AstraZeneca and Ionis Pharmaceuticals (February 2018).

6. Drug development initiatives by start-ups have received financial support in terms of venture funding and research grants. In fact, more than USD 4.1 billion, across 118 instances of grants, venture capital rounds and public offerings, has been invested in these companies since 2010. Across all the funding rounds, the most active investors include (in terms of participation in funding rounds) Omega Funds, Flagship Pioneering, Polaris Partners, venBio Select, Oxford Finance, OrbiMed Advisors, Morningside Group, Limulus Venture Partners, Cormorant Asset Management, AJU IB Investment and Sibling Capital.

7. Several prominent scientists (over 100) have made significant contributions in advancing the clinical development efforts, and therefore, have emerged as key opinion leaders in this field. Examples of prominent universities and hospitals that have been engaged in conducting breakthrough research in this domain include (in alphabetical order, no selection criteria) Icahn School of Medicine, UC San Diego School of Medicine, University of Michigan, University of Oxford and Vanderbilt University Medical Center.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the chronic kidney disease market in the long term.

Chapter 3 provides an introduction to chronic kidney disease and its associated comorbidities. It features a detailed discussion on the development, symptoms and stages of the condition, factors influencing disease progression and the various treatment regimens that are available in the market. It also includes a discussion on the epidemiology of the disease and the associated economic burden across various regions.

Chapter 4 includes information on over 160 molecules that are currently approved / under development for therapeutic use. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (clinical, preclinical / discovery stage), type of molecule (small molecule or biologic), treatment type (disease modifying agent or drugs offering symptomatic relief), mechanism of action, and route of administration of the drug candidates. In addition, it presents certain key insights derived from the study, which include a heptagon representation highlighting the distribution of the marketed and pipeline molecules based on different clinical indications. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of drug candidates across various indications, dosing frequencies and stages of development. Additionally, the chapter features a regional landscape of developers engaged in this domain, distributed on the basis of the location of their headquarters.

Chapter 5 features an analysis of the clinical and commercial attractiveness of the drugs designed for the treatment of CKD and its associated comorbidities. The drugs are plotted on a 2X2 matrix, with clinical attractiveness (abscissa) and commercial attractiveness (ordinate) as the two axes.
The clinical attractiveness of a drug is determined by sample size of its trial (highest phase), route of administration, treatment type (disease modifying agent and drugs offering symptomatic relief) and dosage frequency. The commercial attractiveness of a drug is determined by the target population size, expected launch date and the company size.

Chapter 6 highlights the key unmet needs associated with the management and treatment of chronic kidney disease. The chapter provides detailed analysis of unmet needs that were identified from views expressed by patients / experts across different platforms, such as social media posts, recent publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful sentiment analysis and word cloud analysis, summarizing the opinions expressed across public portals.

Chapter 7 presents an analysis of the competitive landscape of companies involved in the development of novel therapeutics for the treatment of chronic kidney disease. It is based on the number of molecules in the pipelines of different players (taking into consideration the current status of development) and company size (in terms of number of employees). In this analysis, companies across different regions (North America, Europe and Asia-Pacific) were plotted on 2X2 matrices, having company pipeline strength as the ordinate and company size as the abscissa.

Chapter 8 provides an analysis of KOLs in the field of chronic kidney disease. It features a comprehensive list of principal investigators of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also features a comparative analysis, highlighting those KOLs who have relatively more experience in this domain.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including product development and commercialization, R&D agreements, technology / product licensing agreements, other licensing agreements, mergers / acquisitions and clinical trial collaborations) and the most common forms of deals / agreements that have been established between 2015 to 2018.

Chapter 10 presents details on various investments received by companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, in the period between 2010 and July 2018, highlighting the growing interest of the venture capital community and other strategic investors in this market.

Chapter 11 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 12 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report:

1. Aarhus University
2. Achillion Pharmaceuticals
3. Advantech Capital
4. AJU IB Investment
5. Akebia Therapeutics
6. Albany College of Pharmacy and Health Sciences
7. Alexandria Venture Investments
8. Alexion Pharmaceuticals
9. Algomedix
10. Allegheny Financial Group
11. Amgen
12. Amyndas Pharmaceuticals
13. Angion Biomedica
14. Anthera Pharmaceuticals
15. apceth Biopharma
16. Apellis Pharmaceuticals
17. AptaBio Therapeutics
18. Apollo Hospitals
19. Ardelyx
20. Armetheon
21. Asahi Kasei Pharma
22. Astellas Pharma
23. AstraZeneca
24. Aurinia Pharmaceuticals
25. Avexxin
26. Barclays Bank
27. Bay City Capital
28. Bayer
29. Baylor College of Medicine
30. Beijing Anzhen Hospital
31. Bichat-Claude Bernard Hospital
32. Bill & Melinda Gates Foundation
33. BIOCAD
34. BioVirtus
35. BLR Bio
36. Boehringer Ingelheim
37. Boryung Pharmaceutical
38. Bristol-Myers Squibb
39. Calliditas Therapeutics
40. California Institute of Renal Research
41. Cara Therapeutics
42. CARB-X
43. Cash Capital
44. Cedars-Sinai Medical Center
45. Cellmid
46. Celgene
47. Centre Hospitalier Universitaire
48. China Medical University Hospital
49. Children's Mercy Hospital
50. ChemoCentryx
51. Chugai Pharmaceutical
52. Clough Capital
53. Complexa
54. Concert Pharmaceuticals
55. Cormorant Asset Management
56. Cowen Healthcare Investments
57. Cowin Capital Group
58. Creighton University
59. CTI Life Sciences Fund
60. CuraGen
61. Cycad Group
62. Daiichi Sankyo
63. DaVita Clinical Research
64. Sumitomo Dainippon Pharma
65. DiaMedica Therapeutics
66. Dimerix
67. Dong-A ST
68. Dongguk University
69. Duke University
70. Dynavax Technologies
71. Eastern Capital
72. EcoR1 Capital
73. Edmond de Rothschild Investment Partners
74. Efung Capital
75. Ege University
76. ElexoPharm
77. Eli Lilly and Company
78. Elite Capital
79. Ember Therapeutics
80. Epidarex Capital
81. Epigen Biosciences
82. Espero BioPharma
83. Evanston Northwestern Hospital
84. Evotec
85. Flagship Pioneering
86. Foresee Pharmaceuticals
87. F-Prime Capital Partners
88. Fresenius Medical Care
89. Fudan University
90. Galencia
91. Galectin Therapeutics
92. Gazi University
93. Gabriele d’Annunzio’ University
94. Genentech
95. Genexine
96. Genkyotex
97. Georgetown University
98. George Washington University
99. Gilead Sciences
100. GlaxoSmithKline
101. Glycadia Pharmaceuticals
102. GNI Group
103. Goldfinch Bio
104. Goldman Sachs
105. Gujarat Kidney Foundation
106. Hadassah Medical Center
107. Hamad Medical
108. H.C. Wainwright
109. Hanmi Pharmaceutical
110. Hansa Medical
111. HBM Healthcare Investments
112. Hennepin Healthcare
113. Heidelberg University
114. Hercules Capital
115. Hermed Capital
116. Hoffmann-La Roche
117. Hospital Aleman
118. Human Genome Sciences
119. Hydra Biosciences
120. Icahn School of Medicine at Mount Sinai
121. Idera Pharmaceuticals
122. Indiana University
123. Innovation Network Corporation of Japan
124. Inositec
125. inRegen
126. Inselspital
127. Ionis Pharmaceuticals
128. Iran University of Medical Sciences
129. Ironwood Pharmaceuticals
130. Italian Hospital
131. JAFCO
132. Janssen Pharmaceuticals
133. Japan Tobacco International
134. Jiangsu Maslech Medical Technology
135. Johns Hopkins University
136. JPMorgan Chase
137. Kadmon
138. KAI Pharmaceuticals
139. KBP Biosciences
140. Keryx Biopharmaceuticals
141. Kezar Life Sciences
142. King's College London
143. KISSEI Pharmaceutical
144. Klotho Therapeutics
145. Knight Therapeutics
146. Konkuk University
147. Korea Investment Partners
148. Kyowa Hakko Kirin
149. Kyung Hee University
150. L&F Research
151. La Jolla Pharmaceutical
152. Lanthio Pharma
153. Lawson Health Research Institute
154. LCR Clinical Research
155. Lexicon Pharmaceuticals
156. LG Life Sciences
157. Limulus Venture Partners
158. London Health Sciences Centre
159. Longitude Capital
160. Lonza
161. Mallinckrodt Pharmaceuticals
162. Mannkind Corporation
163. Mariel Therapeutics
164. Maruishi Pharmaceutical
165. Massachusetts General Hospital
166. Mayo Clinic
167. McMaster University
168. Medicxi Ventures
169. MedImmune
170. Medical University of Graz
171. Medipal Holdings
172. Medison Pharma
173. Megapharm
174. Merck Serono
175. Merck Sharp & Dohme
176. Michigan State University
177. Mission Therapeutics
178. Mitsubishi Tanabe Pharma
179. Morningside Ventures
180. MRL Ventures Fund
181. National Taiwan University Hospital
182. Nephrotic Syndrome Study Network
183. New Enterprise Associates
184. Necker-Enfants Malades Hospital
185. NorthShore University HealthSystem
186. Novadiol
187. Novartis Institutes for Biomedical Research
188. Novartis Pharmaceuticals
189. Novo Nordisk
190. NOXXON Pharma
191. Omega Funds
192. OPKO Health
193. Orange County Research Center
194. Oraxion Therapeutics
195. OrbiMed
196. Orbis Biosciences
197. Oregon Health & Science University
198. Ottawa Hospital Research Institute
199. Otsuka Pharmaceuticals
200. Oxford Finance
201. University of Oxford
202. Palladio Biosciences
203. Pappas Ventures
204. Paranta Biosciences
205. Pfizer
206. Pfizer Venture Investments
207. Pharmacosmos
208. Ping An Ventures
209. PKD Foundation
210. Polaris Partners
211. Prometic Life Sciences
212. Proteomics International
213. Proteon Therapeutics
214. Qiming Venture Partners
215. Queen Mary’s Hospital
216. Reata Pharmaceuticals
217. Redx Pharma
218. Regulus Therapeutics
219. Relypsa
220. Resverlogix
221. Retrophin
222. Rigel Pharmaceuticals
223. Roche
224. Rockwell Medical
225. UC San Diego School of Medicine
226. Sahlgrenska University Hospital
227. Sandoz
228. Sangel Capital
229. Sanifit
230. Sanofi
231. SCOHIA PHARMA
232. SDIC Venture Capital
233. Sectoral Asset Management
234. Seoul National University
235. Seoul St. Mary's Hospital
236. Serodus
237. Serum Institute of India
238. Severance Hospital
239. St. George's University
240. Fosun Pharma
241. Samsung Medical Center
242. Shenyang Sunshine Pharmaceutical
243. Shenzhen Hepalink Pharmaceutical
244. Shield Therapeutics
245. Sibling Capital Ventures
246. Silicon Valley Bank
247. Silver Creek Pharmaceuticals
248. SK Group
249. Sofinnova Ventures
250. Stanford University
251. Taipei Medical University
252. Taisho Pharmaceutical
253. Takeda Pharmaceuticals
254. Teijin Pharma
255. Tel Aviv Sourasky Medical Center
256. The Medical University of South Carolina
257. Toronto General Hospital
258. Theravance Biopharma
259. The George Institute for Global Health
260. The Rogosin Institute
261. Third Rock Ventures
262. Thynk Capital
263. Tokai University
264. Trevi Therapeutics
265. Tricida
266. Trisaq
267. TR-Pharm
268. Tufts Medical Center
269. UnicoCell Biomed
270. Unicyte
271. The University of Alabama
272. University Hospitals Birmingham
273. The University of British Columbia
274. University of California
275. University of Calgary
276. University of Cincinnati
277. University of Frankfurt
278. University of Giessen
279. University of Guadalajara
280. University of Illinois
281. University of Kentucky
282. University of Leeds
283. University of Louisville
284. University of Manitoba
285. University of Maryland
286. University of Michigan
287. University of Minnesota
288. University of Missouri
289. University of North Carolina
290. University of Oklahoma
291. University Hospital Center De Montpellier
292. University of Montreal
293. University of Pennsylvania
294. University of Ulsan
295. University of Utah
296. University of Wisconsin
297. University Hospital Bonn
298. Uppsala University Hospital
299. University of Zurich
300. Vanderbilt University Medical Center
301. Variant Pharmaceuticals
302. venBio Global Strategic Fund
303. venBio Select
304. Venrock Healthcare Capital Partners
305. Verily Life Sciences
306. Vertex Venture Holdings
307. Vidasym
308. Vifor Fresenius Medical Care Renal Pharma
309. Vifor Pharma
310. Visterra
311. Vivo Capital
312. Washington University School of Medicine
313. Watson Laboratories
314. Wellington Management
315. XORTX Therapeutics
316. Yuhan Corporation
317. Zeria Pharmaceutical
318. ZS Pharma


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. An Overview of Chronic Kidney Diseases
3.2.1. Medical Conditions Associated with Chronic Kidney Diseases
3.2.1.1. Alport Syndrome
3.2.1.2. Diabetic Nephropathy
3.2.1.3. Focal Segmental Glomerulosclerosis
3.2.1.4. Glomerulonephritis
3.2.1.5. Nephrotic Syndrome
3.2.1.6. Polycystic Kidney Disease
3.2.1.7. Hypertensive Kidney Disease
3.2.1.8. Pyelonephritis
3.2.2. Stages of Chronic Kidney Disease
3.2.3. Symptoms
3.2.4. Diagnosis
3.2.5. Treatment Options
3.2.5.1. Therapeutics
3.2.5.2. Other Modalities
3.2.7. Kidney Transplant and Implications
4. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS
4.1. Chapter Overview
4.2. Drugs for Chronic Kidney Disease: Marketed and Development Pipeline
4.3. Chronic Kidney Disease: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Route of Administration
4.3.4. Analysis by Target Therapeutic Indication(s)
4.3.5. Analysis by Size of Developer
4.3.6. Analysis by Size and Location of the Players
4.3.7. Analysis of Leading Developers
4.3.8. Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
4.3.9. Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
4.3.10. Geographical Landscape
5. PRODUCT CLINICAL COMMERCIAL ATTRACTIVENESS
5.1. Chapter Overview
5.2. Methodology
5.2.1. Assumptions and Key Parameters
5.3. Affiliated Insights
6. CHRONIC KIDNEY DISEASE: UNMET NEEDS ANALYSIS
6.1. Chapter Overview
6.2. Unmet Needs Analysis in Chronic Kidney Disease
6.2.1. Unmet Needs Expressed in Patient Blogs
6.2.1.1. Methodology
6.2.1.2. Key Insights
6.2.2. Unmet Needs Reported in Published Literature
6.2.2.1. Methodology
6.2.2.2. Key Insights
6.2.3. Unmet Needs Expressed on Social Media Platforms
6.2.3.1. Methodology
6.2.3.2. Key Insights
6.2.4. Unmet Needs Highlighted by Experts
6.2.4.1. Titte Srinivas, Intermountain Medical Centre
6.2.4.2. Brian Clement, Hippocrates Health Institute
6.2.4.3. Frank Brennan, Palliative Care Physician
6.2.4.4. Sarah Brook, Renal Dietitian, Salford Royal NHS Foundation Trust
6.2.4.5. Joseph Selvanayagam, Medical Researcher, Flinders University
6.2.4.6. Vanessa Rojas-Bautista, UC Irvine Health
6.2.5. Concluding Remarks: Key Unmet Needs in Chronic Kidney Disease
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.2.1. Assumptions and Key Parameters
7.3. Company Competitiveness Analysis: Key Insights
7.3.1. Key Players: North America
7.3.2. Key Players: Europe
7.3.3. Key Players: Asia Pacific
8. KOL ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.4. Prominent Key Opinion Leaders
8.5. Most Active Key Opinion Leaders
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Therapeutics for Chronic Kidney Disease: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Novel Therapeutics for Chronic Kidney Disease: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Most Active Players
10.3.5. Most Active Investors
10.4. Concluding Remarks
11. APPENDIX 1: TABULATED DATA
12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS  
LIST OF FIGURES
Figure 3.1 Chronic Kidney Diseases: Epidemiology
Figure 3.2 Diabetic Nephropathy: Disease Progression
Figure 3.3 Chronic Kidney Diseases: Symptoms
Figure 3.4 Chronic Kidney Diseases: Diagnostic Techniques
Figure 3.5 Chronic Kidney Diseases: Treatment Options
Figure 3.6 ACE Inhibitors: Mechanism of Action
Figure 3.7 Statins: Mechanism of Action
Figure 3.8 Loop Diuretics: Mechanism of Action
Figure 3.9 Thiazide Diuretics: Mechanism of Action
Figure 3.10 Kidney Transplant: Associated Challenges
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Molecule
Figure 4.3 Pipeline Analysis: Distribution by Route of Administration
Figure 4.4 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Figure 4.5 Pipeline Analysis: Distribution by Size of Developer
Figure 4.6 Pipeline Analysis: Leading Developers
Figure 4.7 Pipeline Analysis: Distribution by Size and Location of the Players
Figure 4.8 Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
Figure 4.9 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Figure 4.10 Geographical Landscape
Figure 5.1 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Anemia
Figure 5.2 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Diabetic Nephropathy and Nephrotic Syndrome
Figure 5.3 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Focal Segmental Glomerulosclerosis
Figure 5.4 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for IgA Nephropathy
Figure 5.5 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for Lupus Nephritis and Pyelonephritis
Figure 5.6 Clinical Commercial Attractiveness: Phase III and Phase II Molecules for CKD (Indication Unspecified)
Figure 6.1 Unmet Needs Analysis: Overview of the Methodology
Figure 6.2 Unmet Needs in Chronic Kidney Disease: Word Cloud of Patient Blogs
Figure 6.3 Unmet Needs in Chronic Kidney Disease: Needs Highlighted in Published Literature
Figure 6.4 Unmet Needs in Chronic Kidney Disease: Social Media Sentiment Analysis
Figure 6.5 Unmet Needs in Chronic Kidney Disease: Social Media Word Cloud on Total Tweets
Figure 6.6 Unmet Needs in Chronic Kidney Disease: Social Media Word Cloud on Specific Indications
Figure 6.7 Chronic Kidney Disease: Key Unmet Needs
Figure 7.1 Company Competitiveness Analysis: Key Players in North America
Figure 7.2 Company Competitiveness Analysis: Key Players in Europe
Figure 7.3 Company Competitiveness Analysis: Key Players in Asia Pacific
Figure 8.1 KOL Analysis: Geographical Location of Principal Investigators
Figure 8.2 KOL Analysis: Dot-Plot of Principal Investigators
Figure 8.3 KOL Analysis: Most Active Key Opinion Leaders
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Most Active Players
Figure 9.4 Partnerships and Collaborations: Regional Distribution
Figure 9.5 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Figure 10.2 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Figure 10.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Figure 10.5 Chronic Kidney Disease: Summary of Investments, 2010-2018 (USD Million)
Figure 10.6 Funding and Investment Analysis: Most Active Players
Figure 10.7 Funding and Investment Analysis: Most Active Investors
Figure 10.8 Funding and Investment Summary
LIST OF TABLES
Table 3.1 Indicative Values of Focal Segmental Glomerulosclerosis
Table 3.2 Stages of Chronic Kidney Disease
Table 4.1 Chronic Kidney Disease: Marketed and Development Pipeline
Table 5.1 Clinical Trial Analysis: Final Output
Table 8.1 KOL Analysis: List of Principal Investigators
Table 8.2 KOL Analysis: List of Universities and Hospitals
Table 8.3 KOL Analysis: Scoring System
Table 8.4 KOL Profile: Bernard Canaud, Clinical Trials
Table 8.5 KOL Profile: Bernard Canaud, Published Literature
Table 8.6 KOL Profile: Christopher Wilcox, Clinical Trials
Table 8.7 KOL Profile: Christopher Wilcox, Published Literature
Table 8.8 KOL Profile: Csaba P Kovesdy, Clinical Trials
Table 8.9 KOL Profile: Csaba P Kovesdy, Published Literature
Table 8.10 KOL Profile: Ian H de Boer, Clinical Trials
Table 8.11 KOL Profile: Ian H de Boer, Published Literature
Table 8.12 KOL Profile: Stanley Jordan, Clinical Trials
Table 8.13 KOL Profile: Stanley Jordan, Published Literature
Table 9.1 Chronic Kidney Disease: Partnerships and Collaborations, 2015-2018
Table 10.1 Chronic Kidney Disease: Funding and Investments, 2010-2018
Table 10.2 Funding and Investment Analysis: Summary of Investments
Table 11.1 Chronic Kidney Diseases: Epidemiology
Table 11.2 Pipeline Analysis: Distribution by Phase of Development
Table 11.3 Pipeline Analysis: Distribution by Type of Molecule
Table 11.4 Pipeline Analysis: Distribution by Route of Administration
Table 11.5 Pipeline Analysis: Distribution by Target Therapeutic Indication(s)
Table 11.6 Pipeline Analysis: Distribution by Size of Developer
Table 11.7 Pipeline Analysis: Leading Players
Table 11.8 Pipeline Analysis: Distribution by Size and Location of the Players
Table 11.9 Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
Table 11.10 Geographical Landscape Analysis: Distribution by Developers and their Headquarters
Table 11.11 Unmet Needs in Chronic Kidney Disease: Needs Highlighted in Published Literature
Table 11.12 Unmet Needs in Chronic Kidney Disease: Social Media Platforms, Sentiment Analysis
Table 11.13 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2018
Table 11.14 Partnerships and Collaborations: Distribution by Type of Partnership
Table 11.15 Partnerships and Collaborations: Most Active Players
Table 11.16 Partnerships and Collaborations: Regional Distribution
Table 11.17 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 11.18 Funding and Investment Analysis: Cumulative Number of Instances, 2010-2018
Table 11.19 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2018 (USD Million)
Table 11.20 Funding and Investment Analysis: Distribution by Type of Funding, 2010-2018
Table 11.21 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Table 11.22 Chronic Kidney Disease: Summary of Investments, January 2010-July 2018 (USD Million)
Table 11.23 Funding and Investment Analysis: Most Active Players
Table 11.24 Funding and Investment Analysis: Most Active Investors
Table 11.25 Funding and Investment Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report